Hereditary spastic paraplegia (HSP) is a group of inherited neurological disorders that cause progressive stiffness and weakness in the legs. The condition affects roughly 0.1 to 9.6 people per 100,000 worldwide, making it rare but not exceptionally so. At its core, HSP involves a gradual dying-back of the longest nerve fibers in the spinal cord, specifically those that carry movement signals from the brain to the lower body. Because these fibers are the longest in the nervous system, they’re the most vulnerable to the genetic defects that drive the disease.
How HSP Damages the Nervous System
The hallmark of HSP is retrograde axonal degeneration, meaning the nerve fibers deteriorate from their endpoints upward. The two main structures affected are the corticospinal tracts (which carry voluntary movement commands from the brain down to the legs) and the posterior columns (which relay sensory information like vibration and body position back up to the brain). This “length-dependent” pattern explains why the legs are hit first and hardest: the nerve fibers reaching the feet are simply the longest ones in the body, and they’re the first to fail when cellular transport or maintenance goes wrong.
The underlying problem varies by genetic type but often involves disrupted transport of materials along nerve fibers, faulty membrane shaping, or problems with cellular energy production. In some forms, the protective coating around nerves (myelin) isn’t directly damaged at all. Instead, nerve fibers degenerate on their own because the proteins that keep them healthy are missing or defective.
Pure vs. Complex Forms
Doctors classify HSP into two broad categories. Pure (or uncomplicated) HSP mainly causes leg stiffness and weakness, though it can also include mild sensory changes in the feet, such as reduced vibration sense, and bladder urgency or frequency. Many people with pure HSP maintain a relatively stable quality of life for years, even decades.
Complex (or complicated) HSP includes all of those leg symptoms plus additional neurological problems. These can range widely: tremor, seizures, cognitive decline, nerve damage in the hands and feet (peripheral neuropathy), difficulty with coordination (ataxia), upper limb stiffness, and visible changes on brain imaging such as white-matter lesions or a thin corpus callosum. Complex forms tend to appear earlier in life and progress more aggressively.
Genetics and Inheritance Patterns
More than 80 genetic types of HSP have been identified, each labeled with an “SPG” number. The most common by far is SPG4, caused by mutations in the SPAST gene, which accounts for about 40% of cases in North American and northern European populations. SPG3A (from mutations in the ATL1 gene) is the next most common, responsible for roughly 10% of cases and particularly frequent in people whose symptoms began in childhood.
HSP follows several different inheritance patterns depending on the specific gene involved. The pure form is most often autosomal dominant, meaning you only need one copy of the mutated gene, inherited from one parent, to develop the condition. Other forms are autosomal recessive, requiring a defective copy from both parents. A small number of types are X-linked (passed from mother to son) or inherited through mitochondrial DNA. This variety in inheritance patterns means family history can look very different from one HSP family to the next. Some families have an obvious pattern across generations; others may see the condition appear seemingly out of nowhere.
Symptoms and How They Progress
The earliest symptom is usually a subtle stiffness in the legs, often noticed as tripping, difficulty running, or a feeling that the legs don’t move as freely as they should. Over time, walking becomes increasingly effortful. The legs may feel heavy, and balance can deteriorate as sensory feedback from the feet diminishes. Bladder urgency is common even in the pure form.
The rate of progression varies enormously. In many autosomal dominant pure forms, people walk independently for decades, sometimes with the help of ankle braces or a cane. In more aggressive types like SPG11, the most common complex form, most patients lose the ability to walk within one to two decades of their first gait problems. A study of 18 Dutch patients with SPG11 found that 67% were no longer able to walk after an average of about 16 years. In late stages, SPG11 can progress to involve the arms, cause severe difficulty swallowing, and lead to significant cognitive decline. Several patients in that study died of complications between ages 30 and 48. This is notably more severe than typical HSP, and SPG11 should not be taken as representative of the broader group. Many people with pure HSP have a normal or near-normal lifespan.
How HSP Is Diagnosed
Diagnosing HSP can be challenging because its symptoms overlap with other conditions that cause leg stiffness, particularly primary lateral sclerosis (PLS) and multiple sclerosis. In fact, research published in JAMA Neurology found that distinguishing HSP from PLS based on clinical features alone is unreliable in adults who develop symptoms without a clear family history. One clue that may point toward PLS rather than HSP is significant involvement of the arms or speech and swallowing muscles, which is unusual in pure HSP.
The diagnostic process typically starts with clinical criteria first established in the 1980s: progressive leg spasticity, a family history consistent with a genetic pattern, and exclusion of other causes. MRI of the brain and spinal cord helps rule out structural problems, tumors, or inflammatory diseases like multiple sclerosis. The confirmatory step is genetic testing, which can now screen panels of dozens of HSP-related genes simultaneously. Getting a specific genetic diagnosis matters not just for the individual but for family planning, since it clarifies which relatives might be at risk and what inheritance pattern applies.
Managing Spasticity
There is currently no treatment that slows or stops the nerve degeneration in HSP. All available therapies focus on managing symptoms, and spasticity (the constant muscle tightness in the legs) is the primary target. Oral medications that relax muscles are the first-line approach. These can take the edge off stiffness and make walking and stretching easier, though they often cause drowsiness or general muscle weakness as side effects.
For people whose spasticity doesn’t respond well to oral medication, or who can’t tolerate the side effects, a surgically implanted pump that delivers medication directly into the fluid surrounding the spinal cord is an option. This approach uses much smaller doses and avoids many of the systemic side effects. In a small study of HSP patients who received these pumps, three out of four were able to stop their oral medications entirely once the pump reached a stable dose. Some patients also benefit from targeted injections that temporarily weaken specific overactive muscles.
Physical Therapy and Mobility Aids
Regular physical therapy is a cornerstone of HSP management. Structured exercise programs that include squatting, kneeling, and range-of-motion activities have been studied in HSP patients, with sessions as short as 20 minutes, two to six days per week over 12 weeks showing benefits. Robotic-assisted gait training, where a machine helps guide the legs through a normal walking pattern, has shown durable improvements in balance and mobility for people with uncomplicated HSP.
Ankle-foot orthoses (rigid braces that keep the foot in a neutral position) are commonly prescribed to prevent toe-walking and reduce the risk of falls. These braces do come with a trade-off: by limiting ankle movement, they can increase side-to-side trunk sway during walking. For people who already have significant balance issues, this is worth discussing with a physical therapist to find the right fit. As the disease progresses, many people transition from ankle braces to a cane, then forearm crutches, and eventually a wheelchair. Early introduction of mobility aids isn’t a sign of giving up; it conserves energy and reduces the risk of falls that can cause serious injury.
Gene Therapy on the Horizon
While no disease-modifying treatment exists yet, the first gene therapy trials for specific HSP subtypes are now underway. A Phase 1/2 clinical trial is testing a gene replacement therapy for SPG47, a rare childhood-onset form caused by mutations in the AP4B1 gene. The treatment uses a viral vector to deliver a functional copy of the gene directly into the central nervous system. This trial is early-stage, focused first on safety, but it represents the beginning of a new therapeutic approach for a disease that has had none. Similar strategies are being explored for other genetic subtypes, though most remain in preclinical development.